What defines nephritic-range proteinuria and what are the recommended diagnostic work‑up and management steps?

Nephritic-Range Proteinuria: Definition and Management

Nephritic-range proteinuria is not a standard clinical term—you are likely asking about either nephrotic-range proteinuria (>3.5 g/day) or the proteinuria seen in nephritic syndrome (typically <3.5 g/day with hematuria and hypertension). These represent fundamentally different glomerular disease patterns requiring distinct diagnostic and therapeutic approaches. 1

Key Definitions

Nephrotic-Range Proteinuria

• Protein excretion >3.5 g/24 hours (or protein-to-creatinine ratio >3500 mg/g) 2, 1
• Typically accompanied by hypoalbuminemia (<3.0 g/dL), edema, hyperlipidemia, and thrombotic risk 1
• Reflects severe glomerular permeability defects 3

Nephritic Syndrome Proteinuria

• Proteinuria typically <3.5 g/day combined with hematuria, hypertension, and declining kidney function 1
• Carries poorer prognosis than isolated proteinuria 1
• Reflects inflammatory glomerular injury rather than pure permeability defects 1

Diagnostic Work-Up Algorithm

Initial Laboratory Assessment

• 24-hour urine protein or spot protein-to-creatinine ratio to quantify proteinuria 2
• Serum albumin, creatinine, and lipid panel 1
• Urinalysis with microscopy looking specifically for dysmorphic red blood cells and cellular casts 1
• Complete metabolic panel including bicarbonate (target >22 mmol/L per KDIGO) 4

Serological Evaluation

• Complement levels (C3, C4), ANA, anti-dsDNA for lupus 1
• ANCA panel if vasculitis suspected 1
• Hepatitis B, C, and HIV serologies 1
• Serum and urine protein electrophoresis if age >40 or concerning features 3

Kidney Biopsy Indications

• Nephrotic-range proteinuria in adults is an absolute indication for kidney biopsy as the diagnostic gold standard 5
• Biopsy reveals primary glomerulopathies in 49.3% of nephrotic-range cases versus 34.4% in subnephrotic proteinuria 5
• Even subnephrotic proteinuria (300-3500 mg/g) warrants biopsy given substantial ESKD and mortality risk, with each 100 mg/g increase conferring HR 1.05 for adverse outcomes 5
• Electron microscopy is critical to assess foot process effacement pattern (diffuse versus segmental) which guides treatment decisions 2

Common pitfall: Do not delay biopsy in adults with nephrotic-range proteinuria awaiting "conservative management trials"—histologic diagnosis is essential for targeted therapy. 5

Management Framework

Blood Pressure Control

• Target systolic BP <120 mmHg using standardized office measurement 4
• ACE inhibitors or ARBs as first-line agents, uptitrated to maximally tolerated doses 4
• Critical caveat: Do NOT start ACEi/ARB in patients with abrupt-onset nephrotic syndrome before ruling out minimal change disease, as these drugs can precipitate acute kidney injury in this setting 4
• Monitor creatinine and potassium frequently; accept up to 30% creatinine increase if stable 4
• Stop ACEi/ARB if progressive kidney function decline or refractory hyperkalemia develops 4

Proteinuria Reduction Strategy

• Proteinuria goal is typically <1 g/day, though this varies by primary disease 4
• Dietary sodium restriction to <2.0 g/day (<90 mmol/day) is mandatory 4
• Consider delaying ACEi/ARB initiation in podocytopathies (minimal change disease, FSGS) expected to respond rapidly to immunosuppression 4
• Use potassium-wasting diuretics and/or potassium binders to enable continuation of RAS blockade 4
• Intensify sodium restriction and consider mineralocorticoid receptor antagonists (with hyperkalemia monitoring) for refractory proteinuria 4

Edema Management

• Loop diuretics (bolus or continuous infusion) as primary therapy 4
• Amiloride may reduce potassium loss and improve diuresis 4
• Acetazolamide for metabolic alkalosis, though weak diuretic effect 4
• Ultrafiltration or hemodialysis for refractory volume overload 4

Disease-Specific Immunosuppression

For Primary FSGS (with nephrotic syndrome and diffuse foot process effacement): 2

• High-dose prednisone at 1 mg/kg/day (maximum 80 mg) or 2 mg/kg alternate-day (maximum 120 mg) 2
• Continue for minimum 4 weeks and until complete remission, maximum 16 weeks 2
• If complete remission achieved, continue high-dose for 4 weeks post-remission, then taper by 5 mg every 1-2 weeks over 6 months total duration 2
• Patients likely to remit show proteinuria reduction before 16 weeks—do not persist with high-dose steroids if proteinuria remains unremitting, especially with side effects 2

For Secondary FSGS or genetic FSGS: 2

• Do NOT use immunosuppression 2
• Focus on supportive therapy with RAS blockade and BP control 2
• Genetic screening should be considered to exclude monogenic causes before starting immunosuppression 2

Lifestyle Modifications (Synergistic with Medical Therapy)

• Sodium restriction <2.0 g/day 4
• Weight normalization 4
• Smoking cessation 4
• Regular exercise 4
• Patient education to hold ACEi/ARB and diuretics during volume depletion risk (sick days) 4

Critical distinction: The presence versus absence of nephrotic syndrome (not just nephrotic-range proteinuria) determines immunosuppression candidacy in FSGS—patients with proteinuria >3.5 g/day but albumin >30 g/L require monitoring rather than immediate immunosuppression. 2